Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.550
0.00 (0.00%)
Sep 26, 2025, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $115.50 million as of September 26, 2025. Its market cap has increased by 1,072.29% in one year.
Market Cap
115.50M
Enterprise Value
27.87M
1-Year Change
1,072.29%
Ranking
Category
Stock Price
$1.55
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $115.50M, an increase of 14.98%. That is a compound annual growth rate of 2.97%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 26, 2025 | 115.50M | -47.11% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 650.45B |
| Johnson & Johnson | 432.80B |
| AbbVie | 389.72B |
| UnitedHealth Group | 311.62B |
| Novo Nordisk | 242.68B |
| Novartis AG | 238.65B |
| Abbott Laboratories | 232.44B |
| AstraZeneca | 228.75B |